Future FinTech a leading comprehensive financial and digital technology service provider, announced today that on January 7, 2026, its wholly-owned subsidiary, Future FinTech (Hong Kong) Limited ("FTFT HK"), signed a Framework Agreement (the "Agreement"), that outlines preliminary terms for its acquisition of 100% of the shares of TransGen SC Tech Limited ("TransGen").
Pursuant to the Agreement, the acquisition is expected to be completed within 90 calendar days subject to due diligence and a financial audit of TransGen. A formal acquisition agreement will be executed upon a satisfactory outcome, after which both parties will sign a definitive agreement.
TransGen has established a solid foundation in biofactor R&D, which entails processes that leverage naturally occurring compounds that support normal physiological functioning and that have health-promoting effects on disease prevention and overall wellness. TransGen's primary focus is on the high-value therapeutic areas of developing treatments for diabetes and Alzheimer's disease.
TransGen also conducts advanced research on the enrichment and functional properties of microalgal extracellular vesicles – naturally secreted nanoparticles from microalgae. These serve as next-generation nanocarriers for targeted drug delivery and diagnostics by harnessing their natural ability to transfer beneficial biological molecules. TransGen holds 26 invention patents and utility model patents. This includes numerous certifications and designations, including:
Level 2 Biosafety Laboratory Certification, which refers to standards and protocols for laboratories involved in moderate risk infectious agents, which is regulated by China's high-level National Health Commission.
Human Umbilical Cord Mesenchymal Stem Cells Qualification Certificate, that ensures the quality and safety of pharmaceuticals and biological products, issued by China's National Institutes for Food and Drug Control.